Key result
Rosuvastatin is linked to improved myocardial microcirculation, less AF, and lower mortality after CABG.
Why the study?
Postoperative myocardial microcirculation and recovery remain challenging following CABG.
Does perioperative rosuvastatin administration improve myocardial microcirculation and postoperative recovery in patients undergoing CABG?
Cohort (n=216)
Does perioperative rosuvastatin administration improve myocardial microcirculation and postoperative recovery in patients undergoing CABG?
Perioperative rosuvastatin administration in CABG patients improves myocardial microcirculation, cardiac function, and reduces postoperative atrial fibrillation and 1-year mortality.
Answers are grounded in this paper and cite their sources.
May support perioperative rosuvastatin in CABG; leaves open confirmation in randomized trials.
Coronary artery bypass grafting (CABG) is a common intervention for coronary artery disease, but postoperative myocardial microcirculation and recovery remain challenging. This study aimed to evaluate the effects of rosuvastatin calcium on myocardial microcirculation and postoperative outcomes in CABG patients. This retrospective cohort study included 216 patients who underwent CABG between February 2020 and February 2024. Participants were divided into a conventional treatment group ( n = 111) and a rosuvastatin group ( n = 105) receiving additional rosuvastatin calcium (10 mg/day) from 7 days pre-surgery to 28 days post-surgery. Cardiac echocardiography, blood tests (inflammatory markers, lipids, and cardiac enzymes), and New York Heart Association (NYHA) functional classification were assessed preoperatively and 8 weeks postoperatively. Postoperative complications and mortality were monitored during a one-year follow-up. The rosuvastatin group showed significantly improved left ventricular remodeling, with reduced left ventricular end-diastolic diameter (LVEDD, P = 0.022), Left Ventricular Septal Thickness (LVST, P = 0.048), and Left Ventricular Posterior Wall Thickness (LVPWT, P = 0.019). Enhanced systolic function was evidenced by higher LVEF ( P < 0.001) and Left Ventricular Fractional Shortening (LVFS, P < 0.001). Myocardial microcirculation parameters including Left Acceleration Time (AT), Pulsatility Index (PI), and Aortic Pre-Ejection Period (APT) also improved (all P < 0.05). Additionally, the rosuvastatin group had lower postoperative creatine kinase MB isoenzyme (CK-MB, P = 0.012), higher High-Density Lipoprotein Cholesterol (HDL-C, P = 0.003), and reduced incidence of atrial fibrillation ( P = 0.007) and all-cause mortality ( P = 0.026). Rosuvastatin calcium administration significantly improves myocardial microcirculation, cardiac function, and postoperative recovery in CABG patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a cohort in Coronary artery disease (n=216). Rosuvastatin calcium vs. Conventional treatment was evaluated on Myocardial microcirculation and postoperative outcomes. Rosuvastatin calcium administration improved myocardial microcirculation and reduced atrial fibrillation and all-cause mortality in patients undergoing CABG.
Synapse has enriched 10 related papers. Consider them for comparative context: